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Abstract Antibodies directed to tumour necrosis factor-a
(TNF-a) are very effective in treating paediatric Crohn’s
disease (CD). Over the last few years, research has provided
important new insights into how to optimise this treatment’s
effectiveness. Research on predictors for anti-TNF treat-
ment responsiveness has revealed potential markers, but
data on their accuracy in paediatric CD patients are lagging
behind. Also, new evidence has become available on the
safety profile of anti-TNF antibodies that suggests the
assumed increased malignancy risk seen in patients on anti-
TNF and thiopurine combination treatment may be linked
more to thiopurine use and not to anti-TNF treatment. In
addition, the early results of CT-P13, an inflix-
imab biosimilar, in CD patients confirm the expected sim-
ilarity with its originator. Thus, the effectiveness of anti-
TNF antibody treatment is slowly improving, its malig-
nancy risk is lower than assumed, and its costs are reduced
by the introduction of equally effective biosimilars. Toge-
ther, these trends allow for a more prominent role for anti-
TNF antibodies in future treatment of paediatric CD.
Key Points
The number of predictive markers of anti-tumour
necrosis factor (TNF) treatment responsiveness in
Crohn’s disease (CD) is growing, but their
implementation into clinical care for paediatric CD
patients is hampered by a lack of evidence for their
applicability in the paediatric population.
New evidence suggests that the increased risk of
malignancies seen in patients treated with anti-TNF
thiopurine combination therapy is not linked to anti-
TNF treatment in itself, implying a slightly more
favourable benefit–risk ratio for anti-TNF treatment
than previously assumed.
Early results confirm the expected efficacy and
safety similarity between the infliximab biosimilar
CT-P13 and its originator in paediatric CD.
1 Introduction
Crohn’s disease (CD) is an inflammatory bowel disease
(IBD) of unknown origin. It is a chronic, relapsing-remit-
ting disease characterised by gastrointestinal symptoms,
weight loss and fatigue, co-existing with increased con-
centrations of inflammatory proteins in blood and stool,
and an inflamed intestine. CD may have a complicated
disease course with the formation of fistulas or intestinal
strictures. Immunosuppressive treatment is required for
inducing and maintaining disease remission and preventing
development of these complications. Childhood onset CD
develops in approximately four per 100,000 children [1].
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The paediatric disease course usually is more extensive and
progressive than adult-onset CD, and as a result, more
intense treatment is required [2, 3]. After diagnosis, ster-
oids and exclusive enteral nutrition (EEN) are regularly
started first, to induce remission, together with thiopurines
or methotrexate (MTX) to maintain remission.
Anti-tumour necrosis factor-a (anti-TNF-a) antibodies
have been shown to be very effective in inducing and
maintaining remission in therapy refractory paediatric CD
patients [4, 5]. Anti-TNF treatment not only induces
remission of clinical symptoms, it also restores mucosal
tissue integrity, denoted as endoscopic remission [6]. Since
its approval, researchers have searched for ways to opti-
mise anti-TNF antibody usage to increase response rates
and to prolong the duration of disease remission. Based on
their findings, the use of anti-TNF antibodies in managing
paediatric CD has significantly evolved over time. This
article highlights new insights in the treatment’s mecha-
nisms of action, discusses optimisation methods for anti-
TNF therapy, new data on malignancy risk, and efficacy
and safety data on anti-TNF biosimilars in paediatric CD.
2 Pathogenesis of Crohn’s Disease (CD)
and Tumour Necrosis Factor (TNF)
The pathogenesis of CD is highly complex and still not
fully understood. CD is a multifactorial disease in which
genetic predisposition, microbial and dietary environmen-
tal pressure, and susceptibilities of the immune system lead
to aberrant inflammatory responses to luminal microbiota
and concomitant autoimmune responses. Although a cure
has not yet been found, manipulating one of these factors
does alleviate disease. For example, diversion of luminal
content with a stoma, which drastically alters environ-
mental pressure, reduces mucosal inflammation in the
bowel distal to the stoma. In addition, dietary intervention
with EEN, which affects luminal microbial composition,
also inhibits inflammation and can restore the integrity of
the mucosal layer. Lastly, inhibiting the immune response
also has strong beneficial effects, as most clearly evidenced
by the effect of immune-suppressive and immune-modu-
lating interventions on CD. A key problem in the
chronicity of CD is the development of immune memory
driven by T lymphocytes (T cells) that reside in the
intestinal lamina propria, secrete interferon-c and cause
reactivation of the disease upon recognition of their envi-
ronmental activating trigger [7]. Effective elimination or
inhibition of this cell population may reduce the chance of
disease re-activation and explains why T cells are an
important target in CD treatment strategies.
TNF is an inflammatory cytokine mainly produced by
macrophages, although it can also be produced by many
other leukocytes, for example T cells. It is produced as a
transmembrane protein (tmTNF) and a soluble form
(sTNF). TNF-a is an important factor for orchestrating
cellular immune responses and plays a crucial role in host
defence to pathogens and killing of malignant cells. TNF
signals via two receptors: TNF receptor type 1 (TNFR1),
expressed in almost all cell types, and TNFR2, expressed
on leukocytes only. Ligation of the receptor results in a
complex signalling cascade leading to the production of a
wide variety of proteins involved in cell survival, prolif-
eration, differentiation, migration, and apoptosis. When
TNF concentrations in blood become very high, an acute
phase reaction in the liver ensues, causing fever and
cachexia.
3 Mechanism of Action of Anti-TNF Antibodies
in CD
Multiple mechanisms of action may contribute to the
beneficial effect of anti-TNF antibody therapy in CD
(Fig. 1). Both the antibody’s binding fragment (FAB)
region and the fragment crystallisable (FC) region exert
immunomodulatory properties. The FAB regions of
infliximab (IFX) and adalimumab (ADA) specifically bind
to TNF-a molecules. Upon binding with its FAB region,
anti-TNF antibodies block and neutralise the signalling
potential of TNF. Additionally, anti-TNF antibodies bound
to a tmTNF-expressing target cell suppress pro-inflamma-
tory cytokine production or induce apoptosis in the target
cell, a process denoted as reverse signalling [8–10].
Although it was anticipated that anti-TNF antibodies
would primarily exert their beneficial function in CD by
neutralising TNF function through its FAB regions, it is
now recognised that the FC tail of the antibody is important
for effectiveness. Etanercept—a TNF receptor/im-
munoglobulin G fusion protein, capable of neutralising
sTNF—has been shown to be ineffective in CD [11].
Secondly, certolizumab pegol—a PEGylated FAB frag-
ment of an anti-TNF antibody that lacks an FC region—
had only low efficacy in CD [12]. The poor efficacy of
these biologicals that are effective for the treatment of
other chronic inflammatory diseases (rheumatoid arthritis,
psoriatic arthritis and ankylosing spondylitis among others)
may suggest that the FC region has a crucial role in
inducing immunomodulation in CD. The FC region enables
bound antibodies to elicit complement-dependent cyto-
toxicity (CDC) and antibody-dependent cell-mediated
cytotoxicity (ADCC) [13]. Secondly, it enables an anti-
body–antigen complex to bind with cells presenting an FC
receptor, such as macrophages. Based on in vitro experi-
ments, it is suggested that TNF–anti-TNF immune com-
plexes may lead to the induction of immunosuppressive
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macrophages, able to produce anti-inflammatory proteins,
inhibit T-cell proliferation and promote wound healing
[14, 15]. The induction of these immunosuppressive mac-
rophages may partly explain the higher effectiveness of
anti-TNF antibodies that possess an FC region, but this
hypothesis still needs to be proven.
4 Efficacy of Anti-TNF Antibodies
Both IFX and ADA are efficacious in the treatment of
paediatric CD and are considered equally effective—
although a head-to-head comparison is lacking [16]. They
can both be used to induce and maintain remission in
paediatric CD patients. The available prospective trials
demonstrate that more than 80% of therapy refractory
patients respond to induction treatment with anti-TNF
antibodies [4, 5, 17]. They further demonstrate that anti-
TNF antibodies are able to maintain remission up to 1 year
in approximately 45–83% of patients. The variation in
these remission rates largely depends on patient or treat-
ment factors, as will be discussed further below. Anti-TNF
antibodies are also effective in closing perianal fistulas in
children with CD: after 2–4 months of treatment, approx-
imately 64% showed complete fistula closure (range
54–100% [18–20]), and after 1 year of treatment, 40–68%
showed complete closure [5, 20].
Unfortunately, there still is a lack of a direct, head-to-
head comparison of the efficacy of anti-TNF monotherapy
with that of the alternative therapies in use—EEN or cor-
ticosteroids for remission induction and thiopurines or
MTX for remission maintenance [16]. The pivotal trials of
both IFX and ADA in paediatric CD did not have a control
group, and since their approval, no prospective trial has
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Fig. 1 Overview of the mechanisms of action of anti-tumour necrosis
factor (TNF) antibodies. Displayed are four mechanisms of action of
anti-TNF antibodies in treating Crohn’s disease (CD). Via its binding
fragment (FAB) region, anti-TNF antibodies can (1) neutralise both
soluble (s) TNF and transmembrane (tm) TNF and (2) elicit reverse
signalling that can reduce pro-inflammatory cytokine production of
the tmTNF? cell or induce apoptosis. Through its fragment
crystallisable (FC) region, (3) complement and natural killer (NK)
cells—among others—can bind to the antibodies and can elicit
apoptosis through complement-dependent cytotoxicity and antibody-
dependent cell-mediated cytotoxicity. Moreover, (4) macrophages
(Mu) can bind to the antibody–antigen complex, which leads to the
induction of immunosuppressive macrophages (Muind) able to
produce anti-inflammatory proteins, inhibit T-cell proliferation and
promote wound healing
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been published that compares the effectiveness of anti-TNF
antibodies with alternative treatments. Currently, a trial is
ongoing that compares the efficacy of remission induction
with IFX, prednisolone or EEN in newly diagnosed pae-
diatric CD patients, but results are not yet available [21].
Thus, there is currently no reliable way to compare the
efficacy of anti-TNF antibodies to alternative treatment
options.
5 Optimising Treatment
5.1 Patient Characteristics Impacting Effectiveness
Patient characteristics can have a high impact on drug
effectiveness. In the pivotal ADA trial, IFX-experienced
patients were only half as likely to achieve disease remis-
sion during follow-up than IFX-naı¨ve patients [5]. Sec-
ondly, the authors reported that younger age and shorter
disease duration were associated with higher remission
rates, a finding confirmed by several observational trials
[18, 22–24]. The third factor influencing remission rates in
this trial was baseline C-reactive protein (CRP). Patients
with lower CRP were more likely to achieve remission
during follow-up. However, this finding conflicts with lit-
erature in adult CD patients, where several trials found
high baseline CRP to be associated with higher remission
rates [25–27].
5.2 Combination Therapy and Therapeutic Drug
Monitoring
Besides patient characteristics, some treatment options are
known to impact treatment effectiveness and allow further
treatment optimisation. Currently, there are two methods
being used to improve the effectiveness of anti-TNF anti-
bodies: combination therapy with an immunomodulator
and monitoring of therapeutic drug levels (TDM). Evi-
dence on the relative higher effectiveness of combination
therapy comes from adult CD literature. The Study of
Biologic and Immunomodulator Naive Patients in Crohn’s
Disease (SONIC) trial [28] in adult CD patients who were
naı¨ve to azathioprine (AZA) and anti-TNF antibodies
demonstrated that the addition of AZA to IFX treatment
increases the rate of corticosteroid-free remission and
endoscopic remission at 1 year. However, this result was
achieved in AZA-naı¨ve patients, and it is not known if
combination therapy is also superior in AZA refractory
patients, which is important since many paediatric CD
patients indicated for anti-TNF therapy are AZA refractory.
Additionally, adult CD literature demonstrates that con-
comitant immunomodulatory usage increases anti-TNF
drug levels and reduces their immunogenicity rates, which
may explain the increase in treatment effectiveness [29].
Thus, although evidence of increased effectiveness is
lacking in paediatric CD, based on adult CD literature, it is
likely that combination therapy is more effective, at the
cost of increased risk of adverse effects. The current CD
treatment guideline thus suggests to ‘‘allow concomitant
AZA treatment in the first 6 months of IFX therapy and
then consider stopping AZA, but individualization of the
strategy is required based on prediction variables’’ [16].
Another method used to increase effectiveness is TDM.
Drug level measurements are typically timed preceding an
infusion, resulting in trough levels. IFX trough levels are
considered therapeutic when roughly between 3 and 7 lg/
ml, based on adult CD literature [30–32]. Whether TDM
increases the effectiveness of IFX has not been tested in
paediatric CD, but a prospective, randomised controlled
trial (RCT) assessed this in adult IBD patients with
stable response to maintenance IFX [33]. This trial
showed that dose screening and optimisation during
stable response was able to increase the rate of remission
in patients with sub-therapeutic levels. Subsequent TDM
was demonstrated more cost-effective than clinically
based dosing over a 1-year follow-up period. It did not
increase 1-year remission rates—the primary efficacy
endpoint—but it did reduce the number of flares [TDM-
vs clinically based dosing: 1 year remission 69% (88/128)
vs 66% (81/123), P = 0.686; patients with flares 7% (9/
128) vs 17% (21/123), P = 0.018]. Additionally, a second
RCT compared dose intensification of IFX based on TDM
versus that based on clinical symptoms; results are only
available as an abstract [34]. Adult CD patients who
started with IFX induction (5 mg/kg) were randomised at
week 14 into 3 groups: two groups received TDM-based
dose intensification and one received dose intensification
based on clinical symptoms alone. After 1 year, TDM-
based dose intensifications had not led to higher effec-
tiveness in the primary outcome, i.e. steroid-free remis-
sion plus endoscopic absence of ulcers [TDM 21/45
(47%) and 14/37 (38%) vs clinically based 16/40 (40%),
P = not significant]. Thus, in adult CD patients, TDM
does not always increase the effectiveness of IFX. So far,
it has only been demonstrated beneficial in patients in
stable remission under IFX treatment, by reducing the risk
of sub-therapeutic levels, and by increasing cost-effec-
tiveness. Since the risk of sub-therapeutic IFX levels is
higher in paediatrics, TDM may be more beneficial for
children than for adults [35]. Moreover, since both studies
included IBD patients on maintenance, it could be more
beneficial to start TDM at IFX induction. Thus, the value
of TDM needs to be tested in paediatric patients sepa-
rately. Also, when faced with loss of response, TDM can
guide therapeutic decision making [16, 36].
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5.3 Predicting Treatment Response
Predicting patients’ chances to respond to available treat-
ment options can improve overall treatment success by
enabling physicians to directly choose the treatment option
that offers the highest chance for response—also known as
precision treatment. There are three different ways in
which treatment outcome prediction can improve overall
treatment success (Fig. 2). The first is predicting—before
treatment initiation—which patients respond to anti-TNF
treatment and do not respond to alternative treatment
options. Since 80–90% of paediatric CD patients respond
to anti-TNF antibodies, research should focus on predicting
who does not respond to alternative treatment options, e.g.
steroids, EEN and immunomodulators, to limit the delay of
effective treatment initiation. Unfortunately, there are only
very limited data published on this matter. Two trials
assessed predictive markers for steroid responsiveness in
adult IBD patients. Montero-Melendez et al. performed
RNA expression profiling on mucosal biopsies from 28
IBD patients, including 13 CD patients, before they started
with steroid treatment [37]. With the aim of finding the
fewest number of genes with the highest accuracy, the
authors identified a set of 35 genes that could predict
steroid response (sensitive vs resistant within 30 days) with
82% accuracy. This finding still needs replication in pae-
diatric CD patients. Additionally, in adult ulcerative colitis
(UC) patients, RNA expression positivity of glucocorticoid
receptor b (GR-b) was found to correlate with response to
steroids in two separate cohorts [first [38] and second [39]
cohort: 83% (10/12) and 88% (7/8) positivity in steroid-
resistant vs 9% (1/11) and 17% (1/6) in steroid-responsive
patients]. No data are published on the relation between
GR-b and steroid responsiveness in CD patients. Con-
cerning predicting thiopurines’ effectiveness, a method to
predict their tolerability is clinically available: patients
with low or extremely low thiopurine S-methyltransferase
(TPMT) activity are at increased risk of drug-induced
bone-marrow toxicity [40]. By measuring TPMT enzyme
activity and not commencing thiopurines in patients with
extremely low TPMT activity, the risk of treatment failure
is reduced. Some data on predicting MTX responsiveness
are available in the field of adult rheumatology [41], but
this has not been addressed in IBD. Neither are data
available for predicting response to EEN. Thus, only very
limited data are available on predicting responsiveness to
the alternative non-biologic treatment options.
The second way to increase the chance of treatment
success is by predicting who does not respond to anti-TNF
antibodies and may better receive an alternative treatment
option. Research on this topic is complicated by the low
chance of primary non-response in paediatric CD, and
demands relatively large patient samples in order to be
studied. As we discussed previously, some patient char-
acteristics are known to impact anti-TNF treatment suc-
cess, i.e. no previous anti-TNF exposure, younger age and
shorter disease duration are associated with higher anti-
TNF response rates. However, these features are currently
not used to determine who should or should not receive
anti-TNF treatment, since they cannot accurately predict
anti-TNF primary non-response—one exception being IFX
non-responders, who are switched to a drug that does not
target TNF. In adult CD, not in paediatric CD, several trials
have sought baseline biomarkers that can predict anti-TNF
response. Response to anti-TNF antibodies has been asso-
ciated with baseline RNA expression of several genes in
mucosal biopsies [42] and peripheral blood [43], and with
the patients’ genetic make-up [44–49]. Arijs et al.
demonstrated that RNA expression profiles of mucosal
biopsies from adult colonic CD patients were able to
accurately distinguish all IFX responders from IFX non-
responders—response was determined based on change in
endoscopic disease severity at week 4–6 [42]. The authors
reported that the top 5 differentially expressed genes alone
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If the goal of treatment 
prediction is to prevent non-
response, and a patient is 
predicted to respond to both 
treatment options, than this 
prediction does not reveal the 
better option.
If the goal of treatment 
prediction is to prevent non-
response, and a patient is 
predicted to not respond to 
either treatment option, than 
this prediction does not 
reveal the better option.
Second way in which 
treatment outcome prediction 
reveals the better treatment 
option: 
Predicted non-response to anti-
TNF treatment and response to 
an alternative treatment option
First way in which treatment 
outcome prediction reveals 
the better treatment option: 
Response to anti-TNF 
treatment and non- response 
to an alternative treatment 
option
Third way: Once anti-TNF treatment is initiated, patients benefit from a 
timely recognition of a disease relapse. Predicting which patients have high 
risk to lose response helps to timely recognise and act on a relapse.
Fig. 2 Ways in which patients may benefit from treatment outcome
prediction. Displayed are the three ways in which Crohn’s disease
(CD) patients may benefit from treatment outcome prediction related
to anti-tumour necrosis factor (TNF) treatment. The goal or object of
the first two ways of treatment prediction is the same—to prevent
treatment non-response. This can only be achieved by an accurate
prediction of the chance to respond to anti-TNF treatment and a
prediction of the chance to respond to an alternative treatment option.
The third way in which treatment outcome prediction can be
beneficial is by predicting which patients are at high risk of losing
response. EEN exclusive enteral nutrition
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reached perfect accuracy, i.e. 100% [top five genes: TNF-a-
induced protein 6 (TNFAIP6), S100 calcium-binding pro-
tein A8 (S100A8), interleukin-11, G0/G1switch 2 (G0S2),
and S100 calcium-binding protein A9 (S100A9)]. No such
predictive gene set was identified in ileal CD patients.
More recently, West et al. reported high oncostatin M
expression in mucosal tissue to be associated with anti-
TNF response, which may be a promising marker in the
future [50]. These findings now require replication in a
separate cohort of paediatric CD patients before they can
be used in clinical practice to guide treatment choices.
Atreya et al. used a novel approach to predict anti-TNF
response in adult CD patients [51]. They performed
endoscopy with an endomicroscope, which enables
microscopic inspection of the patient’s intestinal mucosal
surface. Mucosal tmTNF? cells in the intestine were then
visualised in vivo by application of fluorescent antibodies
to TNF. Based on the number of tmTNF? cells, the authors
were able to predict week-12 anti-TNF response with a
sensitivity of 85% and a specificity of 92%. However, since
the response rate they found in adult CD patients was much
lower than that known in children, results cannot be simply
extrapolated to children, but require a specific analysis of
this method in children with CD. Furthermore, the use of
these techniques currently remains highly restricted, as
most centres neither have access to nor experience with
endomicroscopy, which limits its application.
Thirdly, it would be beneficial to predict patients at risk
of losing response to anti-TNF antibodies during treatment,
since these patients may need intensified treatment and
more frequent follow-up. There are multiple trials that
addressed this topic. Typically they have a follow-up per-
iod of 1 year and measure a certain marker after the
induction period (roughly at 2–4 months from anti-TNF
antibody initiation) and relate these results to their 1-year
effectiveness outcomes. When measured after the induction
period, lower clinical disease activity [5], lower endoscopic
disease activity [52], lower calprotectin concentrations
[53], lower disease activity measured by sonography [54]
or by magnetic resonance enterography [55, 56], and
higher IFX trough levels [32, 57] are associated with longer
disease remission. In short, all available evidence indicates
that more effective induction treatment results in more
durable disease remission. Assessment of most of these
factors is already part of routine clinical assessment and
assists in timely discovery of treatment inefficacy.
6 Risk of Malignancy
Anti-TNF antibodies have been in use for about 2 decades
and most adverse effects are well established. Serious side
effects include acute and delayed infusion reactions,
serious infections and opportunistic infections
[4, 5, 16, 58, 59]. More uncertainty remains for rare but
serious adverse events. These include rare cases of
malignancies and mortality. Mortality in IBD patients is
primarily linked to serious infections, followed by
malignancy or uncontrolled disease [60]. The risk of
malignancies was thought to be increased by anti-TNF
treatment, as cases of lymphoma and hepato-splenic
T-cell lymphomas (HSTCLs) were being reported in CD
patients treated with both anti-TNF antibodies and
immunomodulators [61, 62]. This was one of the reasons
why, next to the increased serious infection risk, anti-TNF
antibodies were only approved for therapy refractory CD
patients, because of the higher benefit–risk ratio in this
population [63].
Recently, new evidence suggests that the risk of lym-
phoma seems more linked to thiopurine use (± in com-
bination with anti-TNF) than anti-TNF treatment in itself.
A large industry-sponsored, long-term observational reg-
istry of paediatric patients with IBD (DEVELOP;
NCT00606346) was initiated in 2007 to evaluate the long-
term safety profile of IFX and other therapies prescribed
to paediatric IBD patients. In their first publication, using
data from 5766 patients with a median follow-up of 4.7
years and a total of 18 malignancy events, the authors
report that they did not find an increased risk of malig-
nancy and hemophagocytic lymphohistiocytosis (HLH) in
IFX-treated patients compared to a non-CD control pop-
ulation. Instead these risks were increased in thiopurine-
treated patients—with or without biologic exposure [64].
Notably, all (five) HLH cases were patients exposed to
thiopurine and either a primary Epstein Barr virus infec-
tion (4/5) or a cytomegalovirus infection (1/5); none had
been exposed to anti-TNF antibodies. Out of 15 malig-
nancy cases, four were thiopurine related and without
anti-TNF antibody exposure; in the remaining 11 malig-
nancy cases, patients were exposed to both thiopurines
and anti-TNF antibodies. Note that these conclusions were
based on exposure defined as ‘ever exposed’, and in their
discussion the authors acknowledged that, based on their
data, cessation of thiopurine treatment for more than 1
year reduced the malignancy risk, approaching the base-
line risk. Nevertheless, IFX alone did not significantly
increase the malignancy risk; this was only the case when
patients were also—previously or currently—exposed to
thiopurine. This was also the conclusion of a case–control
study on the risk of lymphomas, which reported an
increased risk of T-cell lymphoma for combination ther-
apy (anti-TNF treatment plus thiopurines), but not for
anti-TNF treatment alone [65]. These findings imply a
somewhat more favourable benefit–risk ratio of anti-TNF
treatment than previously assumed, especially when given
as monotherapy—without thiopurines.
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7 Who to Treat and When to Start
Both IFX and ADA were only approved for a restricted
population of paediatric CD patients, namely the therapy
refractory patients with moderately-to-severely active
disease. Yet, their benefit seems higher when given earlier
in the course of disease. It may therefore be more bene-
ficial to start anti-TNF antibodies right after diagnosis
rather than delay the initiation. This is especially true for
patients who are not effectively treated with—i.e. do not
respond to or quickly relapse under—the conventional
non-biologic treatment options (prednisolone or EEN,
combined with AZA or MTX). However, it remains dif-
ficult to predict responsiveness to these therapeutic
options, so further research is needed to assess the benefits
(and risks) of starting anti-TNF antibodies as a first-line
treatment option.
An argument to limit the use of anti-TNF antibodies is
that they are much more expensive than alternative non-
biologic treatment options. However, the prices of anti-
TNF antibodies are bound to fall after the expiration of
their patents and the approval of an increasing number of
biosimilars. Secondly, if anti-TNF antibodies are indeed
more effective than their non-biologic treatment alterna-
tives, this increased efficacy will cause healthcare savings
over time. Reduced costs will improve the cost-effective-
ness of anti-TNF antibodies, which, together with a slightly
more favourable safety profile, are arguments for a wider
use of the drug in the future.
Patients at greater risk of disease complication, such as
strictures and fistulae, would benefit most from an early
initiation with anti-TNF antibodies. For this purpose, the
current guidelines lists seven factors as potentially pre-
dictive of poor outcome—mostly based on clinical expe-
rience [16]. Recently, new results of the Risk Stratification
and Identification of Immunogenetic and Microbial Mark-
ers of Rapid Disease Progression in Children with Crohn’s
Disease (RISK) study were published [66]. This prospec-
tive inception cohort study followed 913 paediatric CD
patients from disease onset up to 3 years after. Baseline
predictive factors for stricturing or penetrating disease at 3
years were older age, African-American race, isolated ileal
disease, and ASCA and CBir1 serum positivity. However,
their combined sensitivity and specificity were low [66%
(95% confidence interval 51–82) and 63% (95% confi-
dence interval) [55–71]. The authors state that the accuracy
was low because of the low prevalence of complications in
their cohort. Due to the low accuracy, the significance of
these predictive factors in clinical decision making is
limited. Thus it remains difficult to accurately determine
patients at high risk of complications.
8 Biosimilars
Biosimilars of IFX have become available on the European
market since the expiration of the patent of the IFX orig-
inator Remicade. The similarity between the IFX
biosimilar CT-P13 (Inflectra, Remsima) and Remicade
was extensively tested in pre-clinical tests by comparing
the treatments’ physicochemical characteristics and by
comparing their biological activities in several models
related to their mechanisms of action. Afterwards, their
similarity was confirmed clinically in two of the indications
of IFX: ankylosing spondylitis and rheumatoid arthritis
[67, 68]. Based on these results, CT-P13 received market
approval for all IFX’s indications, including paediatric CD.
Only recently, the results of a randomised, double-blind,
non-inferiority trial were published comparing the efficacy
and safety of continuing on Remicade with switching to
CT-P13 in patients with various diseases including CD on
stable treatment with Remicade [69]. A total of 482
patients (155 CD patients; 32%) with stable conditions
under IFX treatment were randomised to continue on
Remicade or switch to CT-P13. After 1 year of follow-up,
they reported similar rates of disease worsening (Remi-
cade vs CT-P13: 26 vs 30%) and similar rates of adverse
events (adverse events 70 vs 68%; serious adverse events
10 vs 9%). Notably, the study was not powered to show
non-inferiority in CD specifically, but in the overall pop-
ulation. Additionally, multiple observational trials assessed
the effects of switching from Remicade to CT-P13, and
these were recently combined in a systematic review [70].
The authors combined the data from 11 observational trials
and 1007 IBD patients, and compared these results—i.e.
efficacy, safety and immunogenicity rates of CT-P13—
with the results of Remicade as reported in previously
published trials. Again, they reported no significant dif-
ferences. Currently, only one observational trial assessed
the effect of switching to CT-P13 in paediatric CD [71]. A
total of 32 paediatric CD patients—and 7 UC—were
switched from Remicade to CT-P13. The authors report
that switching seemed to be safe and did not impact effi-
cacy. Thus, the early results confirm the expected similarity
of Remicade and CT-P13 in CD. Yet studies on both
long-term outcome and switching from the originator to the
biosimilar in paediatric CD are still required.
9 Conclusions
Anti-TNF antibody treatment is very beneficial for paediatric
CD patients. Ongoing research is revealing methods to
improve its effectiveness, such as early start after diagnosis,
Anti-TNF Therapy for Paediatric CD: Benefits of New Developments
TDM and combination treatment with an immunomodulator.
Precision treatment could also optimise anti-TNF treatment
effectiveness by improving response rates and preventing
ineffective treatment. While multiple predictive markers are
identified in adult CD patients, data on their accuracy in
paediatric CD patients is lagging behind. As stated, the
assumed increased risk of malignancies under anti-TNF and
thiopurine combination treatment now seems more linked to
thiopurines, revealing a slightly more favourable safety
profile for anti-TNF treatment than assumed, specifically
when given as monotherapy. In addition, the early results of
IFX biosimilar CT-P13 in CD patients confirm the expected
similarity to its originator regarding efficacy and safety. In
summary, the effectiveness of anti-TNF antibody treatment
is slowly improving, its risks seem somewhat lower than
assumed, and its costs are reduced by the introduction of
probably equally effective biosimilars. Together, these
trends allow for a more prominent role for anti-TNF anti-
bodies in future treatment of paediatric CD.
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